Romanian pharmaceutical producer Antibiotice to benefit from EIB guidance on strengthening corporate governance and investment capacity
EIB to advise Romanian medicines manufacturer Antibiotice on updating its corporate governance
Cooperation aims to strengthen company’s capacity to attract financing and support strategic investments
Bolstering competitiveness of Antibiotice to boost economy of Romania
The European Investment Bank (EIB) will advise Antibiotice SA, the largest pharmaceutical company with majority Romanian capital, on strengthening its corporate governance to support future growth. Under a new advisory services agreement, the EIB will work with Antibiotice to align its risk-management framework and business operations with international best practice in the pharmaceutical sector.
The advisory agreement is a continuation of the partnership with the EIB and aims to strengthen Antibiotice’s capacity to attract financing, support future investments and reinforce long-term competitiveness in a rapidly evolving healthcare market. The EIB support will also reinforce transparency, operational oversight and long-term sustainability across the company’s activities.
Antibiotice SA, which is headquartered in the city of Iași, in the northeastern part of Romania, provides over 200 products for human and veterinary use and employs over 1,300 employees. Promoting the company’s competitiveness and growth prospects through stronger governance will also boost economic development and job creation in Romania.
“Ensuring companies like Antibiotice are equipped for long-term investment means better and patient-oriented healthcare, more jobs and a stronger economy,” said EIB Vice-President Ioannis Tsakiris. “This partnership reflects our commitment to helping key industries modernise, attract investment and contribute to Romania’s sustainable growth through InvestEU.”
Antibiotice, which is majority-owned by the Romanian state, is a strategic domestic supplier of pharmaceuticals as well as a significant exporter of them to countries in Europe and around the world.
“This partnership with the EIB represents an important step in strengthening our long-term strategic development and continues the existing relationship” said Antibiotice Director General Ioan Nani. “The expertise and specialized support provided will help us further align with the highest international industry standards, create solid foundations for new investments and support long-term sustainable development. At the same time, they will promote the increase of our company’s international footprint and help maintain our commitment to providing high-quality medicines to both Romanian citizens and international markets.”
The EIB is providing the advisory support through the InvestEU Advisory Hub, which helps public and private entities across the European Union develop sustainable, high-impact investment projects and strengthen institutional capacity.
